ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

AstraZeneca Sets Four CRISPR Deals

by Ann M. Thayer
February 2, 2015 | APPEARED IN VOLUME 93, ISSUE 5

AstraZeneca has set up four collaborations to exploit the genome-editing method of clustered regularly interspaced short palindromic repeats, or CRISPR, for drug research. Its partners are the Wellcome Trust Sanger Institute in Cambridge, England; the Broad and Whitehead Institutes in Cambridge, Mass; the Innovative Genomics Initiative between the University of California, Berkeley, and UC San Francisco; and the instrument firm Thermo Fisher Scientific. AstraZeneca says it will use the research tool widely to identify and validate drug targets in preclinical disease models. It will share cell lines and compounds with its partners and work with them to publish findings around the use of CRISPR.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment